Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Common Equity (2020 - 2025)

Historic Common Equity for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$89.7 million.

  • Foghorn Therapeutics' Common Equity fell 21695.83% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 21695.83%. This contributed to the annual value of -$45.5 million for FY2024, which is 4101.83% up from last year.
  • Foghorn Therapeutics' Common Equity amounted to -$89.7 million in Q3 2025, which was down 21695.83% from -$76.7 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Common Equity ranged from a high of $125.2 million in Q1 2021 and a low of -$97.5 million during Q1 2024
  • In the last 5 years, Foghorn Therapeutics' Common Equity had a median value of -$24.6 million in 2023 and averaged -$3.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 22367.5% in 2021, then plummeted by 6901964.29% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Common Equity stood at $96.9 million in 2021, then crashed by 99.88% to $112000.0 in 2022, then plummeted by 69019.64% to -$77.2 million in 2023, then soared by 41.02% to -$45.5 million in 2024, then tumbled by 96.93% to -$89.7 million in 2025.
  • Its last three reported values are -$89.7 million in Q3 2025, -$76.7 million for Q2 2025, and -$61.7 million during Q1 2025.